-AP
PharmaCyte Biotech ~5% Shareholder, Iroquois Capital, Sends Open Letter To Co. Board: ‘Expresses Disappointment in the Board’s Failure to Articulate a Plan to Maximize Shareholder Value…’
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position
Criticizes the